1 Memorial Sloan Kettering Cancer Center, New York, NY.
J Oncol Pract. 2019 Jan;15(1):e30-e38. doi: 10.1200/JOP.18.00315. Epub 2018 Dec 13.
A shift in outpatient oncology care from the physician's office to hospital outpatient settings has generated interest in the effect of practice setting on outcomes. Our objective was to examine whether medical oncologists' prescribing of drugs and services for older adult patients with advanced cancer is used more in physicians' offices compared with hospital outpatient departments.
This was a retrospective comparative study. SEER-Medicare data (2004 to 2011) were used to identify Medicare beneficiaries diagnosed with advanced breast, colon, esophagus, non-small-cell lung, pancreatic, or stomach cancer. Between physicians' offices and hospital outpatient departments, we compared use of selected likely low-value supportive drugs, low-value therapeutic drugs, chemotherapy-related hospitalizations, and hospice. We used hierarchical modeling to assess differences between settings to account for correlation within physicians.
Compared with patients treated in a hospital outpatient department, those treated in a physician's office setting were more likely to receive erythropoiesis-stimulating agents (odds ratio, 1.72; 95% CI, 1.53 to 1.94) and granulocyte colony-stimulating factors (odds ratio, 1.28; 95% CI, 1.18 to 1.38). For combination chemotherapy and nanoparticle albumin-bound-paclitaxel in patients with breast cancer, there was a trend toward higher use in physicians' offices, although this was not statistically significant. Chemotherapy-related hospitalizations and hospice did not vary by setting.
We found somewhat higher use of several drugs for patients with advanced cancer in physicians' office settings compared with hospital outpatient departments. Findings support research to dissect the mechanisms through which setting might influence physicians' behavior.
从医生办公室到医院门诊的门诊肿瘤护理的转变引起了人们对实践环境对结果的影响的关注。我们的目的是研究与医院门诊部门相比,肿瘤内科医生为老年晚期癌症患者开处方的药物和服务是否更多地用于医生办公室。
这是一项回顾性比较研究。使用 SEER-Medicare 数据(2004 年至 2011 年)来确定被诊断患有晚期乳腺癌、结肠癌、食管癌、非小细胞肺癌、胰腺癌或胃癌的 Medicare 受益人。在医生办公室和医院门诊部门之间,我们比较了选定的可能低价值支持性药物、低价值治疗性药物、与化疗相关的住院治疗和临终关怀的使用情况。我们使用分层模型来评估设置之间的差异,以解释医生之间的相关性。
与在医院门诊部门治疗的患者相比,在医生办公室治疗的患者更有可能接受红细胞生成刺激剂(优势比,1.72;95%置信区间,1.53 至 1.94)和粒细胞集落刺激因子(优势比,1.28;95%置信区间,1.18 至 1.38)。对于乳腺癌患者的联合化疗和纳米白蛋白结合紫杉醇,虽然这在统计学上并不显著,但在医生办公室中使用的趋势更高。化疗相关住院治疗和临终关怀并未因设置而异。
我们发现,与在医院门诊部门治疗的患者相比,在医生办公室治疗的晚期癌症患者使用几种药物的情况略高。这些发现支持研究,以剖析环境如何影响医生行为的机制。